SPONSOR
Chiesi Farmaceutici S.p.A.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 4
Conditions studied: Fabry DiseaseEpidermolysis BullosaJunctional Epidermolysis BullosaEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, JunctionalSkin AbnormalitiesConnective Tissue DiseaseCollagen DiseasesSkin DiseasesGenetic Diseases, Inborn
Chiesi Farmaceutici S.p.A. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Fabry Disease, Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic.
The trial portfolio spans Phase 3, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chiesi Farmaceutici S.p.A.
How many clinical trials has Chiesi Farmaceutici S.p.A. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Chiesi Farmaceutici S.p.A., of which 3 are actively recruiting participants. These trials cover conditions including Fabry Disease, Epidermolysis Bullosa, Junctional Epidermolysis Bullosa. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chiesi Farmaceutici S.p.A. research focus on?
Chiesi Farmaceutici S.p.A. clinical trials span Fabry Disease, Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional, and additional conditions. The research pipeline includes Phase 3, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chiesi Farmaceutici S.p.A. clinical trial?
To participate in a Chiesi Farmaceutici S.p.A. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chiesi Farmaceutici S.p.A. trials with current recruitment status updated daily.
Clinical Trials by Chiesi Farmaceutici S.p.A.
NCT06663358
Recruiting
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Fabry Disease
NCT06917690 Phase 3
Recruiting
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Epidermolysis Bullosa
NCT07666490 Phase 4
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
Asthma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology